

**AMENDMENT TO H.R. 4641, AS REPORTED
OFFERED BY MS. CLARK OF MASSACHUSETTS**

At the end of the bill, add the following

1 **SEC. 2. REAUTHORIZATION OF SUBSTANCE ABUSE TREAT-**
2 **MENT SERVICES FOR CHILDREN AND ADO-**
3 **LESCENTS.**

4 (a) **IN GENERAL.**—Section 514 of the Public Health
5 Service Act (42 U.S.C. 290bb–7) is amended—

6 (1) by striking “abuse” and inserting “use”
7 each place it appears;

8 (2) by striking “children and adolescents” and
9 inserting “children, adolescents, and young adults”
10 each place it appears; and

11 (3) in subsection (f), by striking “for fiscal
12 years 2002 and 2003” and inserting “for each of
13 fiscal years 2017 through 2022”.

14 (b) **TECHNICAL CORRECTION.**—Section 514 of the
15 Public Health Service Act (42 U.S.C. 290bb–9), as added
16 by section 3632 of the Methamphetamine Anti-Prolifera-
17 tion Act of 2000 (Public Law 106–310; 114 Stat. 1236),
18 is redesignated as section 514B.

1 **SEC. 3. ACCESS TO MEDICATION-ASSISTED TREATMENT**
2 **FOR ADOLESCENTS AND YOUNG ADULTS**
3 **DEMONSTRATION PROGRAM.**

4 (a) IN GENERAL.—The Secretary of Health and
5 Human Services, acting through the Director of the Agen-
6 cy for Healthcare Research and Quality (in this section
7 referred to as the “Director”), shall award grants to eligi-
8 ble entities to establish demonstration programs to—

9 (1) expand access to medication-assisted treat-
10 ment for opioid use disorders among adolescents and
11 young adults;

12 (2) identify and test solutions to overcoming
13 barriers to implementation of medication-assisted
14 treatment for adolescents and young adults; and

15 (3) create and distribute for pediatric health
16 care providers resources on medication-assisted
17 treatment training and implementation.

18 (b) ELIGIBLE ENTITIES.—To be eligible to receive a
19 grant under subsection (a), an entity shall—

20 (1) be a State, political subdivision of a State,
21 Indian tribe, tribal organization, professional pedi-
22 atric provider organization, hospital, an institution
23 of higher education, or other appropriate public or
24 nonprofit institution; and

25 (2) certify that it is in compliance with all ap-
26 plicable registration and licensing requirements.

1 (c) APPLICATION.—To seek a grant under this sec-
2 tion, an entity shall submit to the Director an application
3 at such time, in such manner, and containing such infor-
4 mation as the Director may require.

5 (d) DURATION.—An eligible entity may receive funds
6 under this section to carry out a demonstration program
7 described in this section for a period of not greater than
8 3 years. After the first year for which funding is provided
9 to an eligible entity for a demonstration program, funding
10 may be provided under this section for a subsequent year
11 for such program only upon review of such program by
12 the Director and approval by the Director of such subse-
13 quent year of funding.

14 (e) REPORTS.—

15 (1) BY GRANT RECIPIENTS.—Each eligible enti-
16 ty awarded a grant under this section for a dem-
17 onstration program shall submit to the Director
18 progress reports on such demonstration program at
19 such times, in such manner, and containing such in-
20 formation as the Director may require.

21 (2) BY DIRECTOR.—Not later than one year
22 after the date on which all demonstration programs
23 funded under this section have been completed, the
24 Director shall submit to the Committee on Health,
25 Education, Labor, and Pensions of the Senate, and

1 the Committee on Energy and Commerce of the
2 House of Representatives a report that—

3 (A) describes the availability of medication-
4 assisted treatment for adolescents and young
5 adults with opioid use disorders in the United
6 States, including barriers to such treatment;

7 (B) describes the specific demonstration
8 programs carried out pursuant to this section;

9 (C) evaluates the effectiveness of such pro-
10 grams; and

11 (D) provides recommendations for ensuring
12 that medication-assisted treatment is accessible
13 to adolescents and young adults with opioid use
14 disorders.

15 (f) DEFINITIONS.—In this section:

16 (1) The phrase “adolescents and young adults”
17 means individuals between 10 and 25 years of age.

18 (2) The term “medication-assisted treatment”
19 means pharmacological treatments approved by the
20 Food and Drug Administration, in combination with
21 counseling and behavioral therapies.

22 (3) The term “opioid use disorder” means a
23 substance use disorder that is a problematic pattern
24 of opioid use leading to clinically significant impair-
25 ment or distress occurring within a 12-month period.

1 (4) The term “pediatric health care provider”
2 means a provider of primary health care to individ-
3 uals between 10 and 25 years of age and includes
4 pediatricians, family medicine physicians, and gen-
5 eral practice physicians.

6 (5) The term “professional pediatric provider
7 organization” means a national organization whose
8 members consist primarily of pediatric health care
9 providers.

10 (g) AUTHORIZATION OF APPROPRIATIONS.—There is
11 authorized to be appropriated such sums as may be nec-
12 essary to carry out this section.

